Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA
JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Erscheinungsjahr: 2023
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Decker, Thomas (Autor)
Brucker, Cosima (Autor)
Engel, Anne (Autor)
Fasching, Peter A. (Autor)
Goehler, Thomas (Autor)
Jackisch, Christian (Autor)
Janssen, Jan (Autor)
Koehler, Andreas (Autor)
Luedtke-Heckenkamp, Kerstin (Autor)
Lueftner, Diana (Autor)
van Mackelenbergh, Marion (Autor)
Marme, Frederik (Autor)
Nusch, Arnd (Autor)
Rautenberg, Beate (Autor)
Reimer, Toralf (Autor)
Schmidt, Marcus (Autor)
Weide, Rudolf (Autor)
Wimberger, Pauline (Autor)
Roos, Christian (Autor)
Woeckel, Achim (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
